Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Checkpoint Therapeutics (CKPT) stocks in Canada

Learn how to easily invest in Checkpoint Therapeutics stocks.

Checkpoint Therapeutics is a biotechnology business based in the US. Checkpoint Therapeutics stocks (CKPT.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.86 – a decrease of 11.88% over the previous week. Checkpoint Therapeutics employs 10 staff and has a trailing 12-month revenue of around $279,000.

How to buy shares in Checkpoint Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CKPT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Checkpoint Therapeutics stock price (NASDAQ:CKPT)

Use our graph to track the performance of CKPT stocks over time.

Checkpoint Therapeutics shares at a glance

Information last updated 2022-01-16.
Latest market close$2.30
52-week range$2.22 - $5.38
50-day moving average $3.21
200-day moving average $3.01
Wall St. target price$15.80
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.52

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Checkpoint Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Checkpoint Therapeutics price performance over time

Historical closes compared with the close of $2.3 from 2022-01-20

1 week (2022-01-10) N/A
1 month (2021-12-17) -21.77%
3 months (2021-10-18) -27.22%
6 months (2021-07-21) -22.30%
1 year (2021-01-21) -38.34%
2 years (2020-01-21) 17.95%
3 years (2019-01-18) 3.6
5 years (2017-01-20) 11

Checkpoint Therapeutics financials

Revenue TTM $279,000
Gross profit TTM $-15,283,000
Return on assets TTM -44.87%
Return on equity TTM -88.22%
Profit margin 0%
Book value $0.58
Market capitalisation $218.6 million

TTM: trailing 12 months

Checkpoint Therapeutics share dividends

We're not expecting Checkpoint Therapeutics to pay a dividend over the next 12 months.

Checkpoint Therapeutics share price volatility

Over the last 12 months, Checkpoint Therapeutics's shares have ranged in value from as little as $2.22 up to $5.376. A popular way to gauge a stock's volatility is its "beta".

CKPT.US volatility(beta: 1.6)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Checkpoint Therapeutics's is 1.6031. This would suggest that Checkpoint Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Checkpoint Therapeutics overview

Checkpoint Therapeutics, Inc. , a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7. 1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing CK-101, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc.

Stocks similar to Checkpoint Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site